• Pam3CSK4 Workflows for Innate and Neuro-Immune Studies

  2026-09-23

  Use Pam3CSK4 to create a defined TLR1/2 stimulus for macrophage and immune-cell activation assays, then compare that response with neural control of inflammation. Practical workflow guidance emphasizes dose finding, matched controls, and the limits of connecting these distinct experimental systems.

• Gastrin I (human): Assay Reliability Guide

  2026-09-23

  This scenario-based guide explains how Gastrin I (human), SKU B5358, can support controlled gastric acid secretion pathway research and receptor-mediated cell assays. It covers peptide handling, viability-assay interpretation, organoid-model limitations, protocol parameters, and practical vendor-selection criteria.

• 2',7'-Dichlorofluorescein Diacetate for ROS Assays

  2026-09-22

  Use 2',7'-Dichlorofluorescein diacetate for practical, quantitative intracellular ROS measurement across microscopy, flow cytometry, and plate-based workflows. This guide connects assay design with redox-responsive pancreatic cancer nanocarrier research while emphasizing controls, interpretation, and troubleshooting.

• Adiponectin Protects Cognition After Splenectomy

  2026-09-22

  The reference study used an aged-rat splenectomy model to show that adiponectin pretreatment improves postoperative cognitive performance while reducing hippocampal neuroinflammation and oxidative stress. Its antagonist–agonist design links these effects to suppression of the TLR4/MyD88/NF-κB pathway, while also highlighting important limits for clinical translation.

• Alda 1: From Aldehyde Stress to Cardiac Repair

  2026-09-21

  Alda 1 is an ALDH2 activator that connects mitochondrial aldehyde detoxification with cardiomyocyte proliferation. This article explains how to select cardiac models, separate enzyme-level effects from regenerative phenotypes, and interpret emerging evidence across ischemia, pressure overload, and radiation injury.

• 2',7'-Dichlorofluorescein diacetate for ROS Assays

  2026-09-21

  Turn a general redox signal into actionable data for cancer, toxicology, and drug-discovery experiments. This workflow shows how to use 2',7'-Dichlorofluorescein diacetate alongside nanocarrier studies without mistaking oxidative-stress fluorescence for species-specific proof.

• Pretomanid Targets Both Terminal Oxidases in TB

  2026-09-20

  The reference study identifies the cytochrome bcc:aa3 and cytochrome bd terminal oxidases as respiratory branches inhibited by pretomanid, also known as PA-824. Its combination data explain why pairing pretomanid with telacebec and ND-011992 may increase bactericidal activity while limiting resistance in replicating and antibiotic-tolerant Mycobacterium tuberculosis.

• Isochlorogenic Acid A Hydrogel for Wound Repair

  2026-09-19

  A 2026 Gels study developed a multifunctional dressing by co-assembling Isochlorogenic acid A with Fe(III) nanoparticles and embedding them in an amylopectin/carboxymethyl chitosan hydrogel. The composite combined antibacterial activity, favorable mechanical and self-healing properties, enhanced cell migration, inflammatory-marker modulation, and improved wound repair in preclinical testing.

• L-NMMA acetate in NO Pathway Assays

  2026-09-18

  L-NMMA acetate provides a practical loss-of-function control for testing whether nitric oxide signaling drives differentiation, viability, or disease-relevant phenotypes. This guide translates dental follicle-cell findings into reproducible assay workflows, concentration screens, controls, and troubleshooting strategies.

• Self-Adaptive Nanocarriers in Pancreatic Cancer

  2026-09-18

  The ACS Nano study developed DATCPT, a pH/reactive oxygen species-responsive nanocarrier designed to overcome circulation, tumor binding, extracellular-matrix penetration, and metastatic signaling barriers in orthotopic pancreatic cancer. Its sequential activation strategy links tumor acidity with ROS-driven matrix remodeling and camptothecin delivery, providing a useful framework for evaluating multifunctional nanomedicines.

• Vardenafil HCl Trihydrate in PDE5 Assays

  2026-09-17

  Vardenafil HCl Trihydrate supports a connected workflow from quantitative PDE5 inhibition assays to cGMP-dependent smooth muscle relaxation research. Its strong PDE5 potency, measurable PDE isoform selectivity, and compatibility with proteoform-aware studies make it useful for mechanism-first translational experiments.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-17

  A 2025 study found that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, and neuropilin-1 in an antibody-based assay. Its systematic peptide-truncation and tyrosine-modification strategy identifies sequence-dependent effects that warrant validation in cell-based infection and receptor-context models.

• CCK-8 Restores Morphine-Impaired Hippocampal LTP

  2026-09-16

  The reference study showed that CCK-8 restored morphine-impaired hippocampal long-term potentiation in rats and enhanced potentiation in saline-treated controls. Antagonist experiments identified the CCK2 receptor, rather than CCK1, as the principal mediator, providing a pharmacological link between a brain–gut peptide and opioid-related synaptic plasticity.

• (-)-Arctigenin MEK1 Inhibitor Workflow

  2026-09-16

  Use (-)-Arctigenin as a reversible pharmacology probe to dissect LPS–NF-κB and MEK1-linked signaling in macrophage–breast cancer models. This workflow pairs solvent discipline, time-resolved pathway measurements, and EV-miRNA assays so reduced invasion is not mistaken for nonspecific cytotoxicity.

• PLAC1 as a Target in Clear Cell Renal Cell Carcinoma

  2026-09-15

  This study integrates TCGA analysis, experimental validation, PLAC1 knockdown, and high-throughput virtual screening to identify PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma. Amaronol B and canagliflozin reduced PLAC1 expression and restrained ccRCC progression in the reported in vitro models, providing a starting point for target-oriented validation rather than a clinically established treatment.

8613 records 1/575 page Next 12345 下5页 Last page